Molecular Partners (MOLN) announced the presentation of three posters at the American Association for Cancer Research annual meeting 2025, ...

Eastman Chemical Co. saw earnings increase in the first quarter compared to Q1 2024, and CEO Mark Costa expressed confidence ...

The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence ...

The same strong reputation continues today as the MMSC Department celebrates 75 years of science saving lives. “UD students ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its ...

Molecular Partners AG’s MOLN share price has surged by 5.04%, which has investors questioning if this is right time to sell.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch ...

Upconversion is a phenomenon in which low-energy photons are combined to produce a higher-energy photon. This process requires the successive absorption of two photons to emit a high-energy photon. As ...

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell ...